Ginkgo Bioworks Holdings Inc expected to post a loss of $1.57 a share - Earnings Preview
Ginkgo Bioworks Holdings Inc
DNA, DNA is expected to show a fall in quarterly revenue when it reports results on August 7 for the period ending June 30 2025The Boston Massachusetts-based company is expected to report a 26.0% decrease in revenue to $41.61 million from $56.21 million a year ago, according to the mean estimate from 4 analysts, based on LSEG data.
LSEG's mean analyst estimate for Ginkgo Bioworks Holdings Inc is for a loss of $1.57 per share.
The current average analyst rating on the shares is "sell" and the breakdown of recommendations is 1 "strong buy" or "buy," no "hold" and 3 "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Ginkgo Bioworks Holdings Inc is $8.00, about 78.5% below its last closing price of $14.28
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Mar. 31 2025 | -1.73 | -1.77 | -1.68 | Beat | 5.1 |
Dec. 31 2025 | -1.49 | -1.77 | -2.00 | Missed | -13 |
Sep. 30 2024 | -2.87 | -2.73 | -0.94 | Beat | 65.5 |
Jun. 30 2024 | -3.20 | -3.12 | -2.80 | Beat | 10.3 |
Mar. 31 2024 | -3.36 | -3.33 | -3.20 | Beat | 4 |
Dec. 31 2023 | -4.17 | -3.87 | -4.40 | Missed | -13.8 |
Sep. 30 2023 | -3.34 | -3.43 | -6.40 | Missed | -86.7 |
Jun. 30 2023 | -2.99 | -3.37 | -3.60 | Missed | -6.8 |
This summary was machine generated August 5 at 22:13 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
